Embecta Corp (EMBC)vsResMed Inc (RMD)
EMBC
Embecta Corp
$9.00
-0.11%
HEALTHCARE · Cap: $526.47M
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 400% more annual revenue ($5.40B vs $1.08B). RMD leads profitability with a 27.5% profit margin vs 12.9%. EMBC trades at a lower P/E of 3.8x. RMD earns a higher WallStSmart Score of 70/100 (B).
EMBC
Buy56
out of 100
Grade: C
RMD
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+90.9%
Fair Value
$110.45
Current Price
$9.00
$101.45 discount
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
EMBC profiles as a declining stock while RMD is a mature play — different risk/reward profiles.
EMBC carries more volatility with a beta of 1.06 — expect wider price swings.
RMD is growing revenue faster at 11.0% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 56/100), backed by strong 27.5% margins and 11.0% revenue growth. EMBC offers better value entry with a 90.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading global medical technology firm dedicated to advancing diabetes management through its cutting-edge insulin delivery solutions. As a spin-off from Becton, Dickinson and Company, Embecta leverages innovative technologies and a comprehensive product portfolio—including insulin pens and syringes—to enhance patient care and health outcomes. Committed to operational excellence and customer-centric strategies, the company is strategically positioned to capitalize on growth opportunities in the fast-evolving diabetes care market. With a focus on improving patient experiences, Embecta aims to drive sustainable development and solidify its leadership in the industry.
Visit Website →ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?